Eli Lilly and Company (NYSE:LLY) is Stableford Capital II LLC’s 9th Largest Position

Stableford Capital II LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 26.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,228 shares of the company’s stock after selling 2,600 shares during the period. Eli Lilly and Company makes up about 2.2% of Stableford Capital II LLC’s holdings, making the stock its 9th largest holding. Stableford Capital II LLC’s holdings in Eli Lilly and Company were worth $5,580,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Algert Global LLC grew its holdings in shares of Eli Lilly and Company by 27.9% during the second quarter. Algert Global LLC now owns 504 shares of the company’s stock worth $456,000 after purchasing an additional 110 shares in the last quarter. AMF Tjanstepension AB lifted its position in Eli Lilly and Company by 113.7% during the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after purchasing an additional 176,552 shares during the last quarter. Czech National Bank grew its stake in Eli Lilly and Company by 5.6% in the 3rd quarter. Czech National Bank now owns 160,697 shares of the company’s stock worth $142,368,000 after buying an additional 8,566 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Eli Lilly and Company by 24.3% in the 3rd quarter. GAMMA Investing LLC now owns 14,491 shares of the company’s stock worth $12,838,000 after buying an additional 2,833 shares during the last quarter. Finally, WealthBridge Capital Management LLC raised its position in shares of Eli Lilly and Company by 55.6% during the 3rd quarter. WealthBridge Capital Management LLC now owns 5,249 shares of the company’s stock valued at $4,650,000 after buying an additional 1,876 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 1.4 %

Shares of NYSE:LLY opened at $811.61 on Monday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a 52-week low of $637.00 and a 52-week high of $972.53. The firm has a market capitalization of $770.48 billion, a P/E ratio of 87.74, a P/E/G ratio of 1.71 and a beta of 0.41. The stock has a 50 day moving average price of $783.56 and a 200-day moving average price of $844.18.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a $1.50 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s payout ratio is currently 56.22%.

Eli Lilly and Company announced that its board has authorized a share repurchase plan on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to purchase up to 2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on LLY. Deutsche Bank Aktiengesellschaft cut their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Sanford C. Bernstein began coverage on Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective on the stock. Wolfe Research assumed coverage on Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price for the company. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Finally, Truist Financial increased their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $997.22.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.